药明生物：将于2026年6月1日举行业务更新电话会议

南方财经网05-31 18:12

　　南财智讯5月31日电，药明生物（02269.HK）发布内幕消息公告，公司将于2026年6月1日上午八时正及晚上八时正（香港时间）召开电话会议，就集团业务营运进行“二零二六年业务更新会议简报”。本次会议系根据《香港联合交易所有限公司证券上市规则》第13.09条及《证券及期货条例》第XIVA部有关内幕消息的规定作出，旨在向股东及潜在投资者及时披露最新业务进展。截至2026年4月30日，公司已获得5个“赢得分子”项目（含2个临床三期项目），拥有78个临床三期及25个商业化生产项目；双/多特异性抗体项目达211个，其中3个已进入商业化生产；与跨国大药企A签署框架协议，涵盖未来2年16个项目及未来10年超50亿美元商业化生产潜力；前三大双多抗生产项目预计2026年各贡献超1亿美元收入。公告同时提示前瞻性陈述风险，并说明经调整财务指标的使用依据。

（文章来源：南方财经网）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2639660078?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-31 18:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2639660078","market":"us","top_or_hot":-1,"title":"药明生物：将于2026年6月1日举行业务更新电话会议","media":"南方财经网","content":"<html><body><div>\n<p>　　南财智讯5月31日电，<span><a href=\"https://laohu8.com/S/02269\">药明生物</a></span>（02269.HK）发布内幕消息公告，公司将于2026年6月1日上午八时正及晚上八时正（香港时间）召开电话会议，就集团业务营运进行“二零二六年业务更新会议简报”。本次会议系根据《香港联合交易所有限公司证券上市规则》第13.09条及《证券及<span>期货</span><span></span>条例》第XIVA部有关内幕消息的规定作出，旨在向股东及潜在投资者及时披露最新业务进展。截至2026年4月30日，公司已获得5个“赢得分子”项目（含2个临床三期项目），拥有78个临床三期及25个商业化生产项目；双/多特异性抗体项目达211个，其中3个已进入商业化生产；与跨国大药企A签署框架协议，涵盖未来2年16个项目及未来10年超50亿美元商业化生产潜力；前三大双多抗生产项目预计2026年各贡献超1亿美元收入。公告同时提示前瞻性陈述风险，并说明经调整财务指标的使用依据。</p><p>（文章来源：南方财经网）</p> </div></body></html>","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>药明生物：将于2026年6月1日举行业务更新电话会议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n药明生物：将于2026年6月1日举行业务更新电话会议\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<p>　　南财智讯5月31日电，<span><a href=\"https://laohu8.com/S/02269\">药明生物</a></span>（02269.HK）发布内幕消息公告，公司将于2026年6月1日上午八时正及晚上八时正（香港时间）召开电话会议，就集团业务营运进行“二零二六年业务更新会议简报”。本次会议系根据《香港联合交易所有限公司证券上市规则》第13.09条及《证券及<span>期货</span><span></span>条例》第XIVA部有关内幕消息的规定作出，旨在向股东及潜在投资者及时披露最新业务进展。截至2026年4月30日，公司已获得5个“赢得分子”项目（含2个临床三期项目），拥有78个临床三期及25个商业化生产项目；双/多特异性抗体项目达211个，其中3个已进入商业化生产；与跨国大药企A签署框架协议，涵盖未来2年16个项目及未来10年超50亿美元商业化生产潜力；前三大双多抗生产项目预计2026年各贡献超1亿美元收入。公告同时提示前瞻性陈述风险，并说明经调整财务指标的使用依据。</p><p>（文章来源：南方财经网）</p> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://finance.eastmoney.com/a/202605313755191889.html\">南方财经网</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0516423091.SGD","symbol_name":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","start_time":0,"source_url":"http://finance.eastmoney.com/a/202605313755191889.html","article_id":"2639660078","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2639660078","pubTimestamp":1780222320,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"南财智讯5月31日电，药明生物（02269.HK）发布内幕消息公告，公司将于2026年6月1日上午八时正及晚上八时正（香港时间）召开电话会议，就集团业务营运进行“二零二六年业务更新会议简报”。本次会议系根据《香港联合交易所有限公司证券上市规则》第13.09条及《证券及期货条例》第XIVA部有关内幕消息的规定作出，旨在向股东及潜在投资者及时披露最新业务进展。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0052750758.USD":"富兰克林中国基金A Acc","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","BK1521":"挪威政府全球养老基金持仓","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","02269":"药明生物","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU3063872942.SGD":"FULLERTON LUX FUNDS ASIA EQUITIES \"I\" (SGD) ACC","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","BK1589":"北水核心资产","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK1141":"生命科学工具和服务","LU0823426480.USD":"法巴中国股票经典Dis","BK1576":"医药外包概念","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0823426308.USD":"法巴中国股票基金","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","BK1610":"ETF&股票定投概念","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0359201612.USD":"贝莱德中国基金A2","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","LU0051755006.USD":"摩根大通中国A (dist)","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","SG9999002463.SGD":"LionGlobal China Growth SGD","LU1688375341.USD":"贝莱德中国灵活股票基金","LU1720050803.USD":"安联全方位中国股票基金","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU0181495838.USD":"施罗德新兴亚洲A Acc"},"translate_title":"WuXi Biologics: Business update conference call to be held on June 1, 2026","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1.5},"content_text":"南财智讯5月31日电，药明生物（02269.HK）发布内幕消息公告，公司将于2026年6月1日上午八时正及晚上八时正（香港时间）召开电话会议，就集团业务营运进行“二零二六年业务更新会议简报”。本次会议系根据《香港联合交易所有限公司证券上市规则》第13.09条及《证券及期货条例》第XIVA部有关内幕消息的规定作出，旨在向股东及潜在投资者及时披露最新业务进展。截至2026年4月30日，公司已获得5个“赢得分子”项目（含2个临床三期项目），拥有78个临床三期及25个商业化生产项目；双/多特异性抗体项目达211个，其中3个已进入商业化生产；与跨国大药企A签署框架协议，涵盖未来2年16个项目及未来10年超50亿美元商业化生产潜力；前三大双多抗生产项目预计2026年各贡献超1亿美元收入。公告同时提示前瞻性陈述风险，并说明经调整财务指标的使用依据。（文章来源：南方财经网）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2639660078","isCrawlerRequest":true}